-transparent.png){kind=logo}
[Carfilzomib, lenalidomide, and dexamethasone therapy for refractory and relapsed multiple myeloma: a single-center study of 29 patients]. 2018
Kiyoshi Okazuka, and
Tadao Ishida, and
Kota Sato, and
Kanji Miyazaki, and
Yumiko Yoshiki, and
Yu Abe, and
Nobuhiro Tsukada, and
Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center.
Twenty-nine patients with multiple myeloma were treated with carfilzomib, lenalidomide, and dexamethasone (KLd) therapy. A response better than partial response (PR) was observed in 72.4% patients with relapsed and/or refractory myeloma. Although 13.8% patients developed hypertension, none of them discontinued therapy as they could be managed by appropriate medication. A patient who had an elevated level of BNP prior to initiating KLd therapy developed heart failure. Results from this study demonstrate that KLd therapy is efficacious for treating patients with multiple myeloma; however, they should be carefully monitored for cardiotoxicity.
Related Publications
Kiyoshi Okazuka, and
Tadao Ishida, and
Kota Sato, and
Kanji Miyazaki, and
Yumiko Yoshiki, and
Yu Abe, and
Nobuhiro Tsukada, and
Kenshi Suzuki
January 2015,
The New England journal of medicine,
Kiyoshi Okazuka, and
Tadao Ishida, and
Kota Sato, and
Kanji Miyazaki, and
Yumiko Yoshiki, and
Yu Abe, and
Nobuhiro Tsukada, and
Kenshi Suzuki
July 2021,
Terapevticheskii arkhiv,
Kiyoshi Okazuka, and
Tadao Ishida, and
Kota Sato, and
Kanji Miyazaki, and
Yumiko Yoshiki, and
Yu Abe, and
Nobuhiro Tsukada, and
Kenshi Suzuki
July 2019,
American journal of hematology,
Kiyoshi Okazuka, and
Tadao Ishida, and
Kota Sato, and
Kanji Miyazaki, and
Yumiko Yoshiki, and
Yu Abe, and
Nobuhiro Tsukada, and
Kenshi Suzuki
May 2020,
British journal of haematology,
Kiyoshi Okazuka, and
Tadao Ishida, and
Kota Sato, and
Kanji Miyazaki, and
Yumiko Yoshiki, and
Yu Abe, and
Nobuhiro Tsukada, and
Kenshi Suzuki
April 2017,
Blood cancer journal,
Kiyoshi Okazuka, and
Tadao Ishida, and
Kota Sato, and
Kanji Miyazaki, and
Yumiko Yoshiki, and
Yu Abe, and
Nobuhiro Tsukada, and
Kenshi Suzuki
January 2019,
American journal of hematology,
Kiyoshi Okazuka, and
Tadao Ishida, and
Kota Sato, and
Kanji Miyazaki, and
Yumiko Yoshiki, and
Yu Abe, and
Nobuhiro Tsukada, and
Kenshi Suzuki
October 2015,
British journal of haematology,
Kiyoshi Okazuka, and
Tadao Ishida, and
Kota Sato, and
Kanji Miyazaki, and
Yumiko Yoshiki, and
Yu Abe, and
Nobuhiro Tsukada, and
Kenshi Suzuki
October 2022,
HemaSphere,
Kiyoshi Okazuka, and
Tadao Ishida, and
Kota Sato, and
Kanji Miyazaki, and
Yumiko Yoshiki, and
Yu Abe, and
Nobuhiro Tsukada, and
Kenshi Suzuki
February 2018,
Turkish journal of medical sciences,
Kiyoshi Okazuka, and
Tadao Ishida, and
Kota Sato, and
Kanji Miyazaki, and
Yumiko Yoshiki, and
Yu Abe, and
Nobuhiro Tsukada, and
Kenshi Suzuki
November 2007,
The New England journal of medicine,
